Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-00101 in Pediatric RRP
NCT00038714Phase 2Completed
- Sponsor
- Stressgen Biotechnologies
- Start
- Nov 2001
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of verpasep caltespen in recurrent respiratory papillomatosis (RRP), sponsored by Stressgen Biotechnologies. Primary endpoint: Intersurgical Interval (ISI) at 60 weeks. Started Nov 2001; status: completed.
02
Drugs
verpasep caltespen
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT00038714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038714.